Shares of GlobeImmune Inc. (GBIM) cratered more than 51% on Wednesday as a phase II study of GS-4774 in patients with chronic hepatitis B on long term viral suppression with an oral antiviral treatment failed to meet the primary endpoint of reduction in hepatitis B surface antigen (HBsAg) at week 24.